Scientists at the Institute of Cancer Research, London have developed a groundbreaking blood test using circulating tumor DNA (ctDNA) that provides comprehensive tracking of childhood cancer progression and treatment response.

Relay Therapeutics plans to initiate ReDiscover-2, a Phase 3 trial evaluating RLY-2608 plus fulvestrant in PI3Kα-mutated, HR+/HER2- advanced breast cancer patients, with enrollment target of 540 patients.

Long-term data from the phase III PCS4 trial reveals patients who recovered normal testosterone levels after androgen-deprivation therapy showed a 46% reduction in mortality risk compared to non-recoverers.

BeiGene has terminated development of its anti-TIGIT antibody ociperlimab following a futility analysis showing the drug was unlikely to meet overall survival endpoints in non-small cell lung cancer.

Flatiron Health and NRG Oncology have partnered to implement Flatiron Clinical Pipe, an EHR-to-EDC connector technology, in a multi-center oncology trial to enhance data entry efficiency.

GLP-1 receptor agonists like semaglutide, originally approved for diabetes (Ozempic), have expanded to weight management (Wegovy) and show potential in treating neurocognitive disorders and reducing alcohol cravings.

A randomized clinical trial found that vitamin K2 supplementation significantly reduces the frequency of nocturnal leg cramps (NLCs) in older adults.

New analyses from Theravance Biopharma's Phase 3 trials demonstrate ampreloxetine's selective mechanism of action and durable target engagement in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy patients.

A recent study, the BRAVO trial, examined the impact of blue light cystoscopy versus white light cystoscopy in veterans with non-muscle invasive bladder cancer.

Sun Pharmaceutical has introduced Fexuclue (fexuprazan 40 mg), a novel potassium-competitive acid blocker, as a new treatment option for adults with all grades of erosive esophagitis in India.

Epsilogen has completed the acquisition of TigaTx, combining their expertise in IgE antibodies with TigaTx's IgA antibody platform to create the world's first pan-isotype cancer antibody company.

MindBio Therapeutics has dosed half of the participants in its Phase 2B trial of MB22001 for anxiety and depression in advanced cancer patients.

Exousia Pro's research demonstrates that inhibiting NANOG expression in glioblastoma cells significantly increases the efficacy of temozolomide, with cell death rates substantially higher than with temozolomide alone.

Cardiff Oncology has been granted a new patent (No. 12,263,173) covering the combination treatment of onvansertib with bevacizumab for all bevacizumab-naïve metastatic colorectal cancer patients through 2043.

Arrowhead Pharmaceuticals' plozasiran, a novel treatment for familial chylomicronemia syndrome (FCS), has been filed for review by the European Medicines Agency and is being fast-tracked for potential EU marketing approval.

Investment in neuroscience is increasing, driven by emerging treatments and the potential of psychedelics for conditions like PTSD and depression.

ResQ Pharma's LipidRescue Kit has been granted a PDUFA date of June 2, 2025, by the FDA, marking a significant step toward potential approval.

Edgewise Therapeutics is prioritizing the completion of recruitment for the GRAND CANYON trial for Becker muscular dystrophy in early 2025.

Genentech has requested accelerated FDA approval for Avastin (bevacizumab) to treat glioblastoma, the most common and aggressive type of brain tumor.

Kadimastem and NLS Pharmaceutics are merging to advance their respective drug portfolios, including AstroRx for amyotrophic lateral sclerosis (ALS).